Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 119

Sort by

Sort Order Select

Journal Articles

Safety, tolerability, and activity of the active C1s antibody riliprubart in cold agglutinin disease: a phase 1b study

Shirley D’Sa, Josephine M. I. Vos, Wilma Barcellini, Marek Wardęcki, Laurent Perrin, Graham Barker, Moshe Zilberstein, Michael Storek, Timothy Chow, Alexander Röth

Blood (2024) 143 (8): 713–720.

https://doi.org/10.1182/blood.2023022153

Published: 2024

Includes: Supplemental data

Journal Articles

Cold Agglutinin Disease (CAD) Real-World Evidence (CADENCE) Registry: Update to the Study Design of the First International, Prospective CAD Registry

Alexander Roeth, Wilma Barcellini, Ulrich Jaeger, Yasutaka Ueda, Marc Michel, Quentin A. Hill, Shruti Srivastava, Ronnie Yoo, Catherine M. Broome

Blood (2023) 142 (Supplement 1): 7341.

https://doi.org/10.1182/blood-2023-180678

Published: 2023

Journal Articles

Clonal Hematopoiesis in Patients with Immune Thrombocytopenia: Preliminary Results of a Cross-Sectional Study

Alessandro Bosi, Marta Canzi, Marco Capecchi, Juri Alessandro Giannotta, Andrea Artoni, Wilma Barcellini, Bruno Fattizzo

Blood (2023) 142 (Supplement 1): 2581.

https://doi.org/10.1182/blood-2023-185087

Published: 2023

Journal Articles

Efficacy and Safety of Subcutaneous Ravulizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria Who Received Prior Intravenous Eculizumab: 2-Year Follow-up

Caroline I Piatek, Flore Sicre De Fontbrune, Fahri Sahin, Wolfgang Füreder, Sandra Fatima Gualandro, Wilma Barcellini, Masayo Ogawa, Stephan Ortiz, Ayca Ozol-Godfrey, Jeff Szer, Mustafa Yenerel

Blood (2023) 142 (Supplement 1): 2713.

https://doi.org/10.1182/blood-2023-190060

Published: 2023

Journal Articles

A Phase III Clinical Trial Program Investigating the Efficacy and Safety of Ianalumab in Patients with Primary Immune Thrombocytopenia (VAYHIT1 and VAYHIT2) and Warm Autoimmune Hemolytic Anemia (VAYHIA)

Hanny Al-Samkari, Wilma Barcellini, Nichola Cooper, Waleed Ghanima, Marc Michel, Raymond SM Wong, Francesco Zaja, Fengkui Zhang, Patrick Urban, Alex Allepuz, Justyna Fronczek-Sokol, Jens Haenig, Pascal Edrich, Adam Cuker

Blood (2023) 142 (Supplement 1): 5456.

https://doi.org/10.1182/blood-2023-180647

Published: 2023

Journal Articles

Ianalumab, a Novel Anti-B-Cell Activating Factor (BAFF) Receptor (BAFF-R) Monoclonal Antibody (mAb) in Development for Immune Thrombocytopenia (ITP) and Warm Autoimmune Hemolytic Anemia (wAIHA), Has Demonstrated a Favorable Safety Profile in Sjögren's Syndrome (SjS), Systemic Lupus Erythematosus (SLE) and Chronic Lymphocytic Leukemia (CLL)

Adam Cuker, Hanny Al-Samkari, Wilma Barcellini, Nichola Cooper, Waleed Ghanima, Marc Michel, Raymond SM Wong, Francesco Zaja, Fengkui Zhang, Patrick Urban, Roberto Abi Rached, David J Kuter

Blood (2023) 142 (Supplement 1): 5427.

https://doi.org/10.1182/blood-2023-180055

Published: 2023

Journal Articles

Combined Safety Data for Sutimlimab in Cold Agglutinin Disease: A Post-Hoc Analysis of the Phase 3 Cardinal and Cadenza Studies

Catherine M. Broome, Wilma Barcellini, Yasutaka Ueda, Umer Khan, Reena Patel, Marek Wardęcki, Katarina Kralova, Shruti Srivastava, Alexander Roeth

Blood (2023) 142 (Supplement 1): 3833.

https://doi.org/10.1182/blood-2023-188686

Published: 2023

Journal Articles

Biochemical and Metabolomic Analysis of Glycolytic Activity in Red Blood Cells from Low-Risk Myelodysplastic Syndromes (LR-MDS) Patients and in-Vitro Effect of the Pyruvate Kinase Activator AG-946

Bruno Fattizzo, Cristina Vercellati, Anna Marcello, Parija Patel, Megan Wind-Rotolo, Loredana Pettine, Marcella Bonanomi, Daniela Gaglio, Claudia Leoni, Elisa Fermo, Paola Bianchi, Anna Zaninoni, Wilma Barcellini

Blood (2023) 142 (Supplement 1): 6456.

https://doi.org/10.1182/blood-2023-188316

Published: 2023

Journal Articles

Deciphering the Differential Diagnosis of Inherited Versus Acquired Bone Marrow Failure Syndromes: A Large Cohort Study

Marta Bortolotti, Roochi Trikha, Sarah Salter, Joanna Large, Shreyans Gandhi, Bruno Fattizzo, Wilma Barcellini, Austin Kulasekararaj

Blood (2023) 142 (Supplement 1): 1360.

https://doi.org/10.1182/blood-2023-186516

Published: 2023

Journal Articles

Understanding the Physical and Psychosocial Impacts of Pyruvate Kinase Deficiency: Patient-Led Development of the Pyruvate Kinase Deficiency Life Phase Model

Rachael F. Grace, Lily Cannon, Maaike Eijgenraam, Carl Lander, Laura Miller D'Angelo, Susan Morris, Janie Davis, Parija Patel, Tamara Schryver, Alejandra Watson, Wilma Barcellini

Blood (2023) 142 (Supplement 1): 3691.

https://doi.org/10.1182/blood-2023-181979

Published: 2023

Journal Articles

Patient-Reported Outcomes: Danicopan As Add-on Therapy to Ravulizumab or Eculizumab Versus Placebo in Patients with Paroxysmal Nocturnal Hemoglobinuria and Clinically Significant Extravascular Hemolysis

Caroline I Piatek, Jong-Wook Lee, Morag Griffin, Jun-Ichi Nishimura, Christopher J. Patriquin, Hubert Schrezenmeier, Wilma Barcellini, Jamile Shammo, Anna Gaya, Yogesh Patel, Peng Liu, Karl-Johan Myrén, Flore Sicre De Fontbrune, Jens Panse, Austin Kulasekararaj

Blood (2023) 142 (Supplement 1): 1346.

https://doi.org/10.1182/blood-2023-190015

Published: 2023

Journal Articles

Thrombophilia Screening in Autoimmune Hemolytic Anemia: A Single-Center Cross-Sectional Study

Nicola Cecchi, Marco Capecchi, Juri Alessandro Giannotta, Maria Abbattista, Cristina Novembrino, Massimo Boscolo, Wilma Barcellini, Bruno Fattizzo

Blood (2023) 142 (Supplement 1): 5204.

https://doi.org/10.1182/blood-2023-182146

Published: 2023

Journal Articles

Infectious Complications in Autoimmune Hemolytic Anemia: A Multi-Center Italian Experience

Nicolo Rampi, Bruno Fattizzo, Nicola Cecchi, Edoardo Tamellini, Francesca Morelli, Ilaria Tanasi, Maria Di Perna, Simona Raso, Angelo Gardellini, Dorela Lame, Marica Laurino, Olga Mulas, Antonello Rana, Paola Bianchi, Wilma Barcellini

Blood (2023) 142 (Supplement 1): 5205.

https://doi.org/10.1182/blood-2023-182224

Published: 2023

Journal Articles

Classical Complement Inhibition By SAR445088 (BIVV020) in Adults with Cold Agglutinin Disease: Safety, Tolerability and Activity Results from the Open-Label, Non-Randomized, Single-Dose Phase 1b Study

Shirley D'Sa, Josephine M.I. Vos, Wilma Barcellini, Marek Wardęcki, Laurent Perrin, Graham Barker, Moshe Zilberstein, Michael Storek, Timothy Chow, Alexander Roeth

Blood (2023) 142 (Supplement 1): 1069.

https://doi.org/10.1182/blood-2023-177886

Published: 2023

Journal Articles

Factor B Inhibition with Oral Iptacopan Monotherapy Demonstrates Sustained Long-Term Efficacy and Safety in Anti-C5-Treated Patients (pts) with Paroxysmal Nocturnal Hemoglobinuria (PNH) and Persistent Anemia: Final 48-Week Results from the Multicenter, Phase III APPLY-PNH Trial

Blood (2023) 142 (Supplement 1): 571.

https://doi.org/10.1182/blood-2023-180780

Published: 2023

Journal Articles

Autoimmune hemolytic anemia during pregnancy and puerperium: an international multicenter experience

Bruno Fattizzo, Marta Bortolotti, Norma N. Fantini, Andreas Glenthøj, Marc Michel, Mariasanta Napolitano, Simona Raso, Frederick Chen, Vickie McDonald, Irina Murakhovskaya, Josephine Mathilde Iris Vos, Andrea Patriarca, Maria Eva Mingot-Castellano, Giulio Giordano, Margherita Scarrone, Tomás José González-López, Laura Trespidi, Daniele Prati, Wilma Barcellini

Blood (2023) 141 (16): 2016–2021.

https://doi.org/10.1182/blood.2022018890

Published: 2023

Includes: Supplemental data

Journal Articles

Oral Monotherapy with Iptacopan, a Proximal Complement Inhibitor of Factor B, Has Superior Efficacy to Intravenous Terminal Complement Inhibition with Standard of Care Eculizumab or Ravulizumab and Favorable Safety in Patients with Paroxysmal Nocturnal Hemoglobinuria and Residual Anemia: Results from the Randomized, Active-Comparator-Controlled, Open-Label, Multicenter, Phase III Apply-PNH Study

Blood (2022) 140 (Supplement 2): LBA-2.

https://doi.org/10.1182/blood-2022-171469

Published: 2022

Journal Articles

Long-Term Hemoglobin Response and Reduction in Transfusion Burden Are Maintained in Patients with Pyruvate Kinase Deficiency Treated with Mitapivat

Blood (2022) 140 (Supplement 1): 5313–5315.

https://doi.org/10.1182/blood-2022-169125

Published: 2022

Journal Articles

Hemolytic Markers, Mortality, and Thromboembolic Events in Cold Agglutinin Disease (CAD): A Retrospective Analysis of the Optum Electronic Health Record Database in the United States

Catherine M. Broome, Wilma Barcellini, Alexander Roeth, Alia Karaouni, Florence Joly, Ronnie Yoo, Augustin Terlinden, Ayo Adeyemi, Yola Moride, Quentin A. Hill

Blood (2022) 140 (Supplement 1): 5306–5308.

https://doi.org/10.1182/blood-2022-163232

Published: 2022

Journal Articles

Concomitant Use of Sutimlimab and COVID-19 Vaccines in Patients with Cold Agglutinin Disease from the Phase 3 Cardinal and Cadenza Studies

Bruno Fattizzo, Alexander Roeth, Catherine M. Broome, Umer Khan, Frank Shafer, Matias Cordoba, Wilma Barcellini

Blood (2022) 140 (Supplement 1): 2839–2841.

https://doi.org/10.1182/blood-2022-159988

Published: 2022

NARROW

Safety, tolerability, and activity of the active C1s antibody riliprubart in cold agglutinin disease: a phase 1b study

Cold Agglutinin Disease (CAD) Real-World Evidence (CADENCE) Registry: Update to the Study Design of the First International, Prospective CAD Registry

Clonal Hematopoiesis in Patients with Immune Thrombocytopenia: Preliminary Results of a Cross-Sectional Study

Efficacy and Safety of Subcutaneous Ravulizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria Who Received Prior Intravenous Eculizumab: 2-Year Follow-up

A Phase III Clinical Trial Program Investigating the Efficacy and Safety of Ianalumab in Patients with Primary Immune Thrombocytopenia (VAYHIT1 and VAYHIT2) and Warm Autoimmune Hemolytic Anemia (VAYHIA)

Combined Safety Data for Sutimlimab in Cold Agglutinin Disease: A Post-Hoc Analysis of the Phase 3 Cardinal and Cadenza Studies

Biochemical and Metabolomic Analysis of Glycolytic Activity in Red Blood Cells from Low-Risk Myelodysplastic Syndromes (LR-MDS) Patients and in-Vitro Effect of the Pyruvate Kinase Activator AG-946

Deciphering the Differential Diagnosis of Inherited Versus Acquired Bone Marrow Failure Syndromes: A Large Cohort Study

Understanding the Physical and Psychosocial Impacts of Pyruvate Kinase Deficiency: Patient-Led Development of the Pyruvate Kinase Deficiency Life Phase Model

Patient-Reported Outcomes: Danicopan As Add-on Therapy to Ravulizumab or Eculizumab Versus Placebo in Patients with Paroxysmal Nocturnal Hemoglobinuria and Clinically Significant Extravascular Hemolysis

Thrombophilia Screening in Autoimmune Hemolytic Anemia: A Single-Center Cross-Sectional Study

Infectious Complications in Autoimmune Hemolytic Anemia: A Multi-Center Italian Experience

Classical Complement Inhibition By SAR445088 (BIVV020) in Adults with Cold Agglutinin Disease: Safety, Tolerability and Activity Results from the Open-Label, Non-Randomized, Single-Dose Phase 1b Study

Factor B Inhibition with Oral Iptacopan Monotherapy Demonstrates Sustained Long-Term Efficacy and Safety in Anti-C5-Treated Patients (pts) with Paroxysmal Nocturnal Hemoglobinuria (PNH) and Persistent Anemia: Final 48-Week Results from the Multicenter, Phase III APPLY-PNH Trial

Autoimmune hemolytic anemia during pregnancy and puerperium: an international multicenter experience

Long-Term Hemoglobin Response and Reduction in Transfusion Burden Are Maintained in Patients with Pyruvate Kinase Deficiency Treated with Mitapivat

Hemolytic Markers, Mortality, and Thromboembolic Events in Cold Agglutinin Disease (CAD): A Retrospective Analysis of the Optum Electronic Health Record Database in the United States

Concomitant Use of Sutimlimab and COVID-19 Vaccines in Patients with Cold Agglutinin Disease from the Phase 3 Cardinal and Cadenza Studies

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only